Scarica l'app Stockscreener
6.607
4.02%
0.277
Precedente Chiudi:
$6.33
Aprire:
$6.33
Volume 24 ore:
350.67K
Relative Volume:
0.13
Capitalizzazione di mercato:
$1.90B
Reddito:
$9.77M
Utile/perdita netta:
$-109.00M
Rapporto P/E:
-18.33
EPS:
-0.3604
Flusso di cassa netto:
$-93.83M
1 W Prestazione:
+1.93%
1M Prestazione:
+50.68%
6M Prestazione:
+54.21%
1 anno Prestazione:
+155.22%
Intervallo 1D:
$6.30
$6.62
Intervallo di 1 settimana:
$6.11
$6.72
Portata 52W:
$1.845
$6.76
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
6.605 | 1.82B | 9.77M | -109.00M | -93.83M | -0.3604 |
VRTX
Vertex Pharmaceuticals Inc
|
427.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
708.12 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.74 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.51 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Raymond James | Strong Buy |
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday - MarketBeat
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Five new Taysha hires get 188,000 stock units under Nasdaq rule - Stock Titan
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Investing News Network
Biotech Taysha pairs its Q1 results with a corporate update on May 6 - Stock Titan
Earnings update from Taysha Gene Therapies expected next week - Traders Union
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call ... - Caledonian Record
Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge? - Yahoo Finance
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting - Investing News Network
Taysha to present preclinical data on Rett syndrome gene therapy By Investing.com - Investing.com Canada
Taysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual Meeting - Quiver Quantitative
Taysha Gene Therapies to Present New Preclinical Data - GlobeNewswire
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Taysha Gene Therapies Shares Surge After FDA Grants Breakthrough Therapy Status - MSN
Taysha Gene Therapies stock hits 52-week high at 6.7 USD - Investing.com India
Taysha Gene Therapies, Inc. ($TSHA) CEO and Director 2025 Pay Revealed - Quiver Quantitative
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month HighShould You Buy? - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 6.7 USD By Investing.com - Investing.com South Africa
Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels - Insider Monkey
Executive pay, board seats and auditor up for TSHA (NASDAQ: TSHA) vote - Stock Titan
This is why Taysha Gene Therapies, Inc. (TSHA) is one of the best healthcare penny stocks to buy - MSN
Taysha Gene Therapies (TSHA) making progress on crucial Rett syndrome treatment - MSN
TSHA Stock Jumps As Canaccord Hikes Price Target - StocksToTrade
Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data - MSN
TSHA Jumps As Taysha Gene Therapies Wins Target Hike - StocksToTrade
TSHA Jumps As Taysha Wins Target Hike On Trial Progress - timothysykes.com
Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Exploring a Potential 94% Upside in the Biotech Arena - DirectorsTalk Interviews
Taysha (TSHA) Stock Treasury Trade (Near Lows) 2026-04-16Breakout Signals - Cổng thông tin điện tử Tỉnh Sơn La
Taysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 6.02 USD - Investing.com Australia
Unusually active option classes on open April 16th - TipRanks
Taysha Gene Therapies (NASDAQ:TSHA) Sets New 12-Month HighStill a Buy? - MarketBeat
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 9%Should You Buy? - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages - MarketBeat
This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy - Insider Monkey
5 Best Healthcare Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.83%
2.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):